Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

Article Abstract:

Treating people with impaired glucose tolerance with acarbose may reduce their risk of developing high blood pressure and cardiovascular disease, according to a study of 1,368 patients. The most significant benefit was a 90% lower rate of heart attacks in the patients who took acarbose. Impaired glucose tolerance is considered an early sign of type 2 diabetes.

Evaluation, Cooking, Hypertension, Prevention, Heart attack, Cookery for hypertensives, Glucose intolerance, Acarbose

---

The rosiglitazone story-lessons from an FDA advisory committee meeting

Article Abstract:

A report reveals that the rosiglitazone story of myocardial ischemic risk related with rosiglitazone treatment in patients with type 2 diabetes mellitus conveys lessons for scientists and practitioners.

United States, Health aspects, Diabetics, Myocardial ischemia

---

Rosiglitazone evaluated for cardio-vascular outcomes - An interim analysis

Article Abstract:

The treatment of type 2 diabetes with Rosiglitazone and its resulting long-term effect on cardio-vascular system is outlined.

Cardiovascular diseases, Type 2 diabetes, Dosage and administration, Clinical report

Similar abstracts:

• Abstracts: Cystatin C and the risk of death and cardiovascular events among elderly persons. Spinal-fusion surgery- the case for restraint
• Abstracts: Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation
• Abstracts: Effect of folate and mecobalamin on hip fractures in patients with stroke. Long-term proton pump inhibitor therapy and risk of hip fracture
• Abstracts: It appears many people with diabetes are unaware of the NSF guidelines. Delivering patient education for people with diabetes
• Abstracts: Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. CCR5 and CXCR4 expression on memory and naive T cells in HIV-1 infection and response to highly active antiretroviral therapy

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.